ImmunityBio, Inc.
ImmunityBio is dedicated to developing innovative immunotherapies that harness the power of the human immune system to treat cancer, infectious diseases, and inflammatory diseases. The company focuses on creating targeted, personalized treatments that strengthen the immune response, aiming to reprogram the patient's immune system to fight disease effectively. They are engaged in extensive research, clinical trials, and collaborations with institutions like the National Cancer Institute to advance cancer prevention and treatment. ImmunityBio actively develops therapies such as NK-92® natural killer cell line, IL-15 superagonist Anktiva (N-803), engineered NK cell therapies, and adenovirus-vectored anti-cancer vaccines, with a focus on making these treatments more accessible and affordable globally.
Industries
Nr. of Employees
large (251-1000)
ImmunityBio, Inc.
Products
Standardized NK research cell line (research reagent)
A standardized NK research cell line provided as a bioanalytical tool for developing reproducible functional cytotoxicity assays and assay validation for research use.
CAR-engineered NK cell therapeutic (clinical example)
A CAR-engineered NK cell therapy developed and tested clinically for B-cell malignancies with reported complete responses in some patients, delivered as an outpatient infusion in clinical trial settings.
IL-15 superagonist immunomodulator for combination oncology therapy
An IL-15 superagonist immunomodulator developed for use in combination with local or systemic cancer therapies, with clinical data supporting activity in combination regimens and regulatory interactions in at least one jurisdiction.
Adenoviral vector-based personalized cancer vaccine platform
A vaccine development platform using adenoviral vectors integrated with neoepitope prediction to deliver patient-specific tumor antigens intended to elicit tailored anti-tumor immune responses.
Standardized NK research cell line (research reagent)
A standardized NK research cell line provided as a bioanalytical tool for developing reproducible functional cytotoxicity assays and assay validation for research use.
CAR-engineered NK cell therapeutic (clinical example)
A CAR-engineered NK cell therapy developed and tested clinically for B-cell malignancies with reported complete responses in some patients, delivered as an outpatient infusion in clinical trial settings.
IL-15 superagonist immunomodulator for combination oncology therapy
An IL-15 superagonist immunomodulator developed for use in combination with local or systemic cancer therapies, with clinical data supporting activity in combination regimens and regulatory interactions in at least one jurisdiction.
Adenoviral vector-based personalized cancer vaccine platform
A vaccine development platform using adenoviral vectors integrated with neoepitope prediction to deliver patient-specific tumor antigens intended to elicit tailored anti-tumor immune responses.
Services
Clinical trial partnerships, centralized IRB coordination and investigator support
Collaboration with clinical investigators and institutions to test immunotherapies in investigator-initiated and sponsor-sponsored trials, including centralized IRB review, multicenter start-up coordination and site onboarding.
Preclinical research and translational study services
Preclinical testing of combination regimens, intra-tumoral and systemic delivery studies, animal model tumor rechallenge experiments and translational assays to generate efficacy and safety data supporting clinical progression.
GMP manufacturing and bioprocess development support
Clinical-scale manufacturing capacity and CMC development support for cell-based therapeutics and biologics, including process development for expansion, formulation and release testing.
Integrated clinical-grade molecular profiling service
End-to-end clinical molecular profiling combining whole-genome, whole-transcriptome and quantitative proteomics performed in CLIA/CAP-accredited laboratory settings to inform neoepitope selection and patient stratification for personalized therapies.
Clinical trial partnerships, centralized IRB coordination and investigator support
Collaboration with clinical investigators and institutions to test immunotherapies in investigator-initiated and sponsor-sponsored trials, including centralized IRB review, multicenter start-up coordination and site onboarding.
Preclinical research and translational study services
Preclinical testing of combination regimens, intra-tumoral and systemic delivery studies, animal model tumor rechallenge experiments and translational assays to generate efficacy and safety data supporting clinical progression.
GMP manufacturing and bioprocess development support
Clinical-scale manufacturing capacity and CMC development support for cell-based therapeutics and biologics, including process development for expansion, formulation and release testing.
Integrated clinical-grade molecular profiling service
End-to-end clinical molecular profiling combining whole-genome, whole-transcriptome and quantitative proteomics performed in CLIA/CAP-accredited laboratory settings to inform neoepitope selection and patient stratification for personalized therapies.
Expertise Areas
- NK cell-based cellular immunotherapy
- Allogeneic/off-the-shelf cell therapy manufacturing and CMC
- Cancer vaccine development with neoepitope-based personalization
- Integrated multi-omics biomarker discovery and patient stratification
Key Technologies
- Standardized NK research cell lines
- Chimeric antigen receptor (CAR) engineering for NK cells
- High-affinity Fc receptor engineering
- IL-15 superagonist and cytokine-based immunomodulators